U.S. FDA's Hahn plans 'significant' work with AstraZeneca in COVID-19 trial inquiry




  • In Business
  • 2020-09-16 02:43:42Z
  • By Reuters
FILE PHOTO: A sign at an AstraZeneca site in Macclesfield
FILE PHOTO: A sign at an AstraZeneca site in Macclesfield  

(Reuters) - The top U.S. Food and Drug Administration official on Tuesday confirmed AstraZeneca Plc's U.S. COVID-19 vaccine trial is on hold, saying the agency is planning to do "very significant work" with the company as it conducts its investigation after an illness in a participant in Britain.

"We're here to protect the American public and we're going to do very significant work with the company to figure out if there's a significant safety issue or not," FDA Commissioner Stephen Hahn said during an Instagram Live interview with Republican U.S. Senator Tim Scott of South Carolina.

"We don't have all facts, so we don't know the causation per se of this, but we really need to look into it. And our prime responsibility is the safety of the American people," Hahn said.

Enrollment in the British drugmaker's global trials of the vaccine, which it is developing with researchers at Oxford University, was paused on Sept. 6, after a participant in its U.K. trial had a serious side effect thought to be a rare spinal inflammatory disorder called transverse myelitis.

The U.K. trial has resumed, as have the company's trials in Brazil and South Africa.

Reuters on Monday reported based on sources that the U.S. trial was still on hold pending FDA and safety panel investigations.

The U.S. government process for reviewing COVID-19 vaccine efforts is being closely watched as some scientists and public health officials fear President Donald Trump will rush to have a vaccine approved before the Nov. 3 presidential election to bolster perception of his handling of the pandemic.


(Reporting by Manojna Maddipatla in Bengaluru, writing by Caroline Humer; Editing by Arun Koyyur and Cynthia Osterman)

COMMENTS

More Related News

Coronavirus (COVID-19) Update: FDA Authorizes First Point-of-Care Antibody Test for COVID-19
Coronavirus (COVID-19) Update: FDA Authorizes First Point-of-Care Antibody Test for COVID-19

Coronavirus (COVID-19) Update: FDA Authorizes First Point-of-Care Antibody Test for COVID-19PR NewswireSILVER SPRING, Md. 23, 2020 /PRNewswire/ -- Today, the U.

Exclusive: Top adviser steps aside from FDA COVID-19 vaccine reviews over potential conflict
Exclusive: Top adviser steps aside from FDA COVID-19 vaccine reviews over potential conflict
  • US
  • 2020-09-23 21:40:20Z

Hana El Sahly, associate professor of virology and microbiology at Baylor College of Medicine in Houston, last year became chairwoman of the FDA's Vaccines and Related Biological Products Advisory Committee - the panel of outside experts that will make recommendations on whether coronavirus vaccines should be approved. In July, however, El Sahly was named one of three lead investigators for Moderna's late-stage COVID-19 vaccine trial, creating a potential conflict of interest. Moderna has said it could have enough data to show whether its vaccine is safe and effective as soon as November.

Why insulin is so expensive
Why insulin is so expensive

The price of insulin has increased dramatically in the past 15 years. Many Type 1 diabetics have struggled to pay for this lifesaving drug.

Most Americans to be vaccinated for COVID-19 by July, CDC chief expects
Most Americans to be vaccinated for COVID-19 by July, CDC chief expects
  • US
  • 2020-09-23 15:26:00Z

U.S. Centers for Disease Control and Prevention head Robert Redfield said he expects there to be about 700 million doses of vaccines available by late March or April, enough for 350 million people. "I think that's going to take us April, May, June, you know, possibly July, to get the entire American public completely vaccinated," Redfield told the U.S. Senate Health, Education, Labor and Pensions Committee. Redfield, U.S. Food and Drug Administration head Stephen Hahn, U.S. National Institute of Allergy and Infectious Diseases head Anthony Fauci and Health and Human Services official Brett Giroir were testifying on the COVID-19 pandemic, which has caused more than 200,000 deaths in the...

U.S. health secretary says AstraZeneca trial in United States remains on hold: CNBC
U.S. health secretary says AstraZeneca trial in United States remains on hold: CNBC
  • US
  • 2020-09-23 12:59:13Z

U.S. Health and Human Services Secretary Alex Azar said on Wednesday that the U.S. trial of AstraZeneca PLC's COVID-19 vaccine remains on hold while the U.S. Food and Drug Administration investigates a patient illness that shut down the global trial. Azar said that the FDA's investigation, which has continued even after the trial has resumed outside of the United States, shows that the agency takes safety of the vaccine seriously.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business